RSS Feeds
Zidovudine-Induced Macular Edema
- Richard G. Lalonde, MD;
- Jean G. Deschênes, MD; and
- Christopher Seamone, MD
Excerpt
Zidovudine has become the standard therapy for patients with altered immunity due to infection with human immunodeficiency virus (HIV). Initially, the drug was studied in patients who were in the advanced stages of HIV infection (1, 2). In that setting, it caused considerable but acceptable toxicity (1,2). More recently, zidovudine was shown to be effective in treating asymptomatic HIV-infected patients with low helper T-cell levels (3). As experience with the drug has grown, knowledge of the range of side effects has increased (1). We report the case of a patient with HIV infection and chronic anterior uveitis who had two
Article and Author Information
-
From Royal Victoria Hospital and McGill University, Montreal, Quebec. For current author addresses, see end of text.
-
Requests for Reprints: Richard Lalonde, MD, Infectious Diseases Clinic, Royal Victoria Hospital, 687 Pine Avenue, Montreal, Quebec H3A 1A1.
-
Current Author Addresses: Drs. Lalonde and Deschênes: Royal Victoria Hospital, 687 Pine Avenue, Montreal, Quebec H3A 1A1.
Dr. Seamone: University of California, San Francisco, Francis I. Proctor Foundation, San Francisco, CA 94143.
